Market Overview

Galena Enrolls First Patient in GALE-301 Cancer Immunotherapy Phase 2 Clinical Trial in Ovarian Cancer

Galena Biopharma (Nasdaq: GALE) today announced the first patient has been enrolled in the Phase 2 trial for GALE-301 (Folate Binding Protein (FBP) vaccine). GALE-301 is a folate receptor alpha-derived, peptide-based cancer immunotherapy administered to HLA-A2 positive patients in combination with granulocyte macrophage-colony stimulating factor (GM-CSF) as an adjuvant treatment to prevent recurrences in high-risk, endometrial and ovarian cancer patients rendered disease-free after completing standard of care therapy.

See full press release

Posted-In: News Guidance Financing Offerings Management Global

 

Related Articles (GALE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters